|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, September 25, 2017 ) Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). Risk factors include family history, age, obesity, obstructive sleep apnea and other diseases, including congenital heart disease, lung disease, liver disease and connective tissue disorders like scleroderma and lupus. Treatment includes sildenafil, prostanoids and calcium channel blockers.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Pulmonary Arterial Hypertension-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 6, 9, 20, 39, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.
Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Request a sample copy at http://www.reportsweb.com/inquiry&RW00011060472/sample
Report Scope
-The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension (Cardiovascular).
-The pipeline guide reviews pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
-The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
-The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
-The pipeline guide reviews key companies involved in Pulmonary Arterial Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
-The pipeline guide evaluates Pulmonary Arterial Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
-The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
-The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular)
For more information about this report at http://www.reportsweb.com/pulmonary-arterial-hypertension-pipeline-review-h2-2017
Reasons to buy
-Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
-Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
-Find and recognize significant and varied types of therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular).
-Classify potential new clients or partners in the target demographic.
-Develop tactical initiatives by understanding the focus areas of leading companies.
-Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
-Formulate corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
-Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
Actelion Ltd
Aerogen Ltd
Arena Pharmaceuticals Inc
Ascendis Pharma A/S
Asklepion Pharmaceuticals LLC
AVEO Pharmaceuticals Inc
Bial-Portela & Ca SA
Biogen Inc
Bristol-Myers Squibb Company
Camurus AB
Capricor Therapeutics Inc
Celsion Corp
Celtaxsys Inc
Chiesi Farmaceutici SpA
Chugai Pharmaceutical Co Ltd
Complexa Inc
Eli Lilly and Company
Galectin Therapeutics Inc
GlaxoSmithKline Plc
HitGen LTD
Insmed Inc
Insys Therapeutics Inc
Johnson & Johnson
Liquidia Technologies Inc
MannKind Corp
Ask for Discount at http://www.reportsweb.com/inquiry&RW00011060472/discount
List of Tables
Number of Products under Development for Pulmonary Arterial Hypertension, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pulmonary Arterial Hypertension-Pipeline by Actelion Ltd, H2 2017
Pulmonary Arterial Hypertension-Pipeline by Aerogen Ltd, H2 2017
Pulmonary Arterial Hypertension-Pipeline by Arena Pharmaceuticals Inc, H2 2017
Pulmonary Arterial Hypertension-Pipeline by Ascendis Pharma A/S, H2 2017
Pulmonary Arterial Hypertension-Pipeline by Asklepion Pharmaceuticals LLC, H2 2017
Pulmonary Arterial Hypertension-Pipeline by AVEO Pharmaceuticals Inc, H2 2017
Pulmonary Arterial Hypertension-Pipeline by Bial-Portela & Ca SA, H2 2017
Pulmonary Arterial Hypertension-Pipeline by Biogen Inc, H2 2017
Pulmonary Arterial Hypertension-Pipeline by Bristol-Myers Squibb Company, H2 2017
Pulmonary Arterial Hypertension-Pipeline by Camurus AB, H2 2017
Pulmonary Arterial Hypertension-Pipeline by Capricor Therapeutics Inc, H2 2017
Pulmonary Arterial Hypertension-Pipeline by Celsion Corp, H2 2017
Pulmonary Arterial Hypertension-Pipeline by Celtaxsys Inc, H2 2017
Pulmonary Arterial Hypertension-Pipeline by Chiesi Farmaceutici SpA, H2 2017
Pulmonary Arterial Hypertension-Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017
Pulmonary Arterial Hypertension-Pipeline by Complexa Inc, H2 2017
Pulmonary Arterial Hypertension-Pipeline by Eli Lilly and Company, H2 2017
Pulmonary Arterial Hypertension-Pipeline by Galectin Therapeutics Inc, H2 2017
Pulmonary Arterial Hypertension-Pipeline by GlaxoSmithKline Plc, H2 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW00011060472/buy/2000
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
